Royalty Pharma to Announce First Quarter 2025 Financial Results on May 8, 2025
Royalty Pharma (Nasdaq: RPRX) has scheduled its first quarter 2025 financial results announcement for Thursday, May 8, 2025, before U.S. markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time on the same day.
Investors can access the conference call details and live webcast through the company's website at their Investors page. A replay of both the call and webcast will remain available on the website for a minimum of 30 days.
Royalty Pharma (Nasdaq: RPRX) ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per giovedì 8 maggio 2025, prima dell'apertura dei mercati statunitensi. La società terrà una conference call e una webcast simultanea alle 8:30 del mattino, ora Eastern dello stesso giorno.
Gli investitori possono accedere ai dettagli della conference call e alla diretta webcast tramite la pagina Investitori del sito web dell'azienda. La registrazione sia della chiamata che della webcast resterà disponibile sul sito per almeno 30 giorni.
Royalty Pharma (Nasdaq: RPRX) ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el jueves 8 de mayo de 2025, antes de la apertura de los mercados estadounidenses. La compañía realizará una conferencia telefónica y una transmisión simultánea a las 8:30 a.m., hora del Este ese mismo día.
Los inversores pueden acceder a los detalles de la conferencia y a la transmisión en vivo a través de la página de Inversores en el sitio web de la empresa. La grabación de la llamada y la transmisión estará disponible en el sitio durante al menos 30 días.
Royalty Pharma (나스닥: RPRX)는 2025년 5월 8일 목요일, 미국 시장 개장 전인 1분기 2025년 재무 결과 발표를 예정하고 있습니다. 회사는 같은 날 동부 표준시 오전 8시 30분에 컨퍼런스 콜과 동시 웹캐스트를 진행할 예정입니다.
투자자들은 회사 웹사이트의 투자자 페이지를 통해 컨퍼런스 콜 세부 정보와 실시간 웹캐스트에 접속할 수 있습니다. 콜과 웹캐스트의 녹화본은 최소 30일간 웹사이트에서 다시 볼 수 있습니다.
Royalty Pharma (Nasdaq : RPRX) a programmé l'annonce de ses résultats financiers du premier trimestre 2025 pour le jeudi 8 mai 2025, avant l'ouverture des marchés américains. La société organisera une conférence téléphonique et un webcast simultané à 8h30, heure de l'Est le même jour.
Les investisseurs peuvent accéder aux détails de la conférence téléphonique et au webcast en direct via la page Investisseurs du site web de l'entreprise. Un replay de la conférence et du webcast restera disponible sur le site pendant au moins 30 jours.
Royalty Pharma (Nasdaq: RPRX) hat die Bekanntgabe der Finanzergebnisse für das erste Quartal 2025 für Donnerstag, den 8. Mai 2025, vor Öffnung der US-Märkte geplant. Das Unternehmen wird am selben Tag um 8:30 Uhr Eastern Time eine Telefonkonferenz und eine gleichzeitige Webcast veranstalten.
Investoren können die Details zur Telefonkonferenz und den Live-Webcast über die Investorenseite der Unternehmenswebsite abrufen. Eine Aufzeichnung der Telefonkonferenz und des Webcasts wird mindestens 30 Tage lang auf der Website verfügbar sein.
- None.
- None.
NEW YORK, April 17, 2025 (GLOBE NEWSWIRE) -- Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its first quarter 2025 financial results on Thursday, May 8, 2025 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:30 a.m. Eastern Time that day.
Conference Call Information
Please visit the “Investors” page of the company’s website at https://www.royaltypharma.com/investors/events/ to obtain conference call information and to view the live webcast. A replay of the conference call and webcast will be archived on the company's website for at least 30 days.
About Royalty Pharma
Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly – directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Novartis’ Promacta, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 15 development-stage product candidates. For more information, visit www.royaltypharma.com.
Royalty Pharma Investor Relations and Communications
+1 (212) 883-6637
ir@royaltypharma.com
FAQ
When will Royalty Pharma (RPRX) release Q1 2025 earnings?
What time is Royalty Pharma's Q1 2025 earnings call?
How can investors access Royalty Pharma's Q1 2025 earnings call?
How long will Royalty Pharma's Q1 2025 earnings call replay be available?
